Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ORPH NASDAQ:TFFP NASDAQ:VTGN NASDAQ:VYNE NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeORPHOrphazyme A/S$1.43$0.51▼$77.77$30.72M1.681.37 million shs941,400 shsTFFPTFF Pharmaceuticals$0.07$0.06$0.06▼$3.23$289KN/AN/AN/AVTGNVistaGen Therapeutics$3.04+4.8%$3.03$1.90▼$3.88$88.97M0.55334,174 shs301,008 shsVYNEVYNE Therapeutics$0.31+1.9%$0.59$0.28▼$4.30$7.90M1.81.63 million shs1.32 million shsWVEWAVE Life Sciences$6.96+2.4%$8.44$5.28▼$16.74$1.08B-1.152.19 million shs2.12 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceORPHOrphazyme A/S0.00%0.00%0.00%0.00%0.00%TFFPTFF Pharmaceuticals0.00%0.00%0.00%0.00%-97.15%VTGNVistaGen Therapeutics+4.83%-13.14%-4.10%+52.00%+1.67%VYNEVYNE Therapeutics+1.94%-1.81%-6.91%-65.17%-83.33%WVEWAVE Life Sciences+2.35%-2.79%-26.81%+5.94%+27.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeORPHOrphazyme A/S$1.43$0.51▼$77.77$30.72M1.681.37 million shs941,400 shsTFFPTFF Pharmaceuticals$0.07$0.06$0.06▼$3.23$289KN/AN/AN/AVTGNVistaGen Therapeutics$3.04+4.8%$3.03$1.90▼$3.88$88.97M0.55334,174 shs301,008 shsVYNEVYNE Therapeutics$0.31+1.9%$0.59$0.28▼$4.30$7.90M1.81.63 million shs1.32 million shsWVEWAVE Life Sciences$6.96+2.4%$8.44$5.28▼$16.74$1.08B-1.152.19 million shs2.12 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceORPHOrphazyme A/S0.00%0.00%0.00%0.00%0.00%TFFPTFF Pharmaceuticals0.00%0.00%0.00%0.00%-97.15%VTGNVistaGen Therapeutics+4.83%-13.14%-4.10%+52.00%+1.67%VYNEVYNE Therapeutics+1.94%-1.81%-6.91%-65.17%-83.33%WVEWAVE Life Sciences+2.35%-2.79%-26.81%+5.94%+27.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceORPHOrphazyme A/S 0.00N/AN/AN/ATFFPTFF Pharmaceuticals 0.00N/AN/AN/AVTGNVistaGen Therapeutics 3.00BuyN/AN/AVYNEVYNE Therapeutics 2.00Hold$6.251,916.13% UpsideWVEWAVE Life Sciences 2.93Moderate Buy$20.33192.15% UpsideCurrent Analyst Ratings BreakdownLatest TFFP, WVE, ORPH, VYNE, and VTGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025WVEWAVE Life SciencesB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/4/2025WVEWAVE Life SciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$21.00 ➝ $18.009/3/2025WVEWAVE Life SciencesLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$26.009/3/2025WVEWAVE Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.008/4/2025WVEWAVE Life SciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$19.007/31/2025VYNEVYNE TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral7/31/2025WVEWAVE Life SciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$24.00 ➝ $21.007/30/2025VYNEVYNE TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/30/2025VYNEVYNE TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral7/28/2025WVEWAVE Life SciencesOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$24.007/16/2025WVEWAVE Life SciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookORPHOrphazyme A/SN/AN/AN/AN/A$2.74 per shareN/ATFFPTFF Pharmaceuticals$730K0.40N/AN/A$4.04 per share0.02VTGNVistaGen Therapeutics$646K144.38N/AN/A$2.44 per share1.25VYNEVYNE Therapeutics$476K16.59N/AN/A$3.53 per share0.09WVEWAVE Life Sciences$108.30M10.23N/AN/A$1.37 per share5.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateORPHOrphazyme A/S-$97.01MN/A0.00N/AN/AN/AN/AN/AN/ATFFPTFF Pharmaceuticals-$21.24M-$6.44N/A∞N/AN/AN/AN/AN/AVTGNVistaGen Therapeutics-$51.42M-$1.78N/AN/AN/A-6,777.08%-74.06%-64.10%11/6/2025 (Estimated)VYNEVYNE Therapeutics-$39.83M-$0.90N/AN/AN/A-8,097.69%-77.57%-63.09%11/6/2025 (Estimated)WVEWAVE Life Sciences-$97.01M-$0.90N/AN/AN/AN/A-78.45%-41.51%11/11/2025 (Estimated)Latest TFFP, WVE, ORPH, VYNE, and VTGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025VYNEVYNE Therapeutics-$0.23-$0.13+$0.10-$0.13$0.15 million$0.07 million8/7/2025Q1 2026VTGNVistaGen Therapeutics-$0.47-$0.47N/A-$0.47$0.22 million$0.24 million7/30/2025Q2 2025WVEWAVE Life Sciences-$0.29-$0.31-$0.02-$0.31$11.52 million$8.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthORPHOrphazyme A/SN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/AVTGNVistaGen TherapeuticsN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioORPHOrphazyme A/S0.141.80N/ATFFPTFF PharmaceuticalsN/AN/AN/AVTGNVistaGen TherapeuticsN/A5.985.98VYNEVYNE TherapeuticsN/A7.607.60WVEWAVE Life SciencesN/A2.562.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipORPHOrphazyme A/S10.74%TFFPTFF Pharmaceuticals15.25%VTGNVistaGen Therapeutics78.39%VYNEVYNE Therapeutics83.78%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipORPHOrphazyme A/SN/ATFFPTFF Pharmaceuticals4.50%VTGNVistaGen Therapeutics2.85%VYNEVYNE Therapeutics4.80%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableORPHOrphazyme A/S14135.31 millionN/ANot OptionableTFFPTFF Pharmaceuticals194.44 million4.24 millionOptionableVTGNVistaGen Therapeutics4030.68 million29.81 millionOptionableVYNEVYNE Therapeutics3025.47 million24.25 millionNot OptionableWVEWAVE Life Sciences240159.14 million120.98 millionOptionableTFFP, WVE, ORPH, VYNE, and VTGN HeadlinesRecent News About These CompaniesWAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by Brokerages5 hours ago | marketbeat.com3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025September 18 at 12:36 PM | zacks.comWave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor ConferencesSeptember 18 at 8:30 AM | globenewswire.comWAVE Life Sciences (NASDAQ:WVE) Stock Price Down 3.5% - What's Next?September 13, 2025 | marketbeat.comWave Life Sciences (WVE) Sees Promising Results From RestorAATion-2 StudySeptember 10, 2025 | finance.yahoo.comRaymond James Reaffirms Their Buy Rating on Wave Life Sciences (WVE)September 9, 2025 | theglobeandmail.comPolar Asset Management Partners Inc. Has $221,000 Stock Holdings in WAVE Life Sciences Ltd. $WVESeptember 9, 2025 | marketbeat.comLeerink Partnrs Has Positive Outlook of WVE FY2027 EarningsSeptember 9, 2025 | marketbeat.comWave Life Sciences Announces Positive Results for WVE-006 StudySeptember 8, 2025 | theglobeandmail.comTrexquant Investment LP Sells 215,940 Shares of WAVE Life Sciences Ltd. $WVESeptember 7, 2025 | marketbeat.comWAVE Life Sciences Ltd. $WVE Stock Position Boosted by Invesco Ltd.September 7, 2025 | marketbeat.comB. Riley ‘aggressive’ buyer of Wave Life on ‘material disconnect’September 6, 2025 | finance.yahoo.comHC Wainwright Reiterates "Buy" Rating for WAVE Life Sciences (NASDAQ:WVE)September 5, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Shares Gap Down - Should You Sell?September 5, 2025 | marketbeat.comWAVE Life Sciences Ltd. $WVE Shares Purchased by Adage Capital Partners GP L.L.C.September 5, 2025 | marketbeat.comWave Crashes Despite Successful RNA Editing in AATD StudySeptember 4, 2025 | biospace.comB683 Capital Management LLC Purchases 140,000 Shares of WAVE Life Sciences Ltd. $WVESeptember 4, 2025 | marketbeat.comJump Financial LLC Trims Stake in WAVE Life Sciences Ltd. $WVESeptember 4, 2025 | marketbeat.comWave RNA editing restores enzyme in genetic condition but underwhelms investorsSeptember 4, 2025 | fiercebiotech.comFWave shares sink on new study results for RNA editing drugSeptember 4, 2025 | finance.yahoo.comForecasting The Future: 7 Analyst Projections For WAVE Life SciencesSeptember 4, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTFFP, WVE, ORPH, VYNE, and VTGN Company DescriptionsOrphazyme A/S NASDAQ:ORPHOrphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.TFF Pharmaceuticals NASDAQ:TFFPTFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.VistaGen Therapeutics NASDAQ:VTGN$3.04 +0.14 (+4.83%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$3.04 +0.00 (+0.16%) As of 05:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.VYNE Therapeutics NASDAQ:VYNE$0.31 +0.01 (+1.94%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$0.31 +0.00 (+0.97%) As of 06:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.WAVE Life Sciences NASDAQ:WVE$6.96 +0.16 (+2.35%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$7.02 +0.05 (+0.79%) As of 09/18/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Why Seagate Is Wall Street's New Favorite AI Infrastructure Play New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
